Baxter

YTD

ALL

Trade Baxter 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BAX

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom.

CEO

Andrew P. Hider

CEOAndrew P. Hider

Employees

38,000

Employees38,000

Headquarters

Deerfield, Illinois

HeadquartersDeerfield, Illinois

Founded

1931

Founded1931

Employees

38,000

Employees38,000

BAX Key Statistics

Market cap

12.69B

Market cap12.69B

Price-Earnings ratio

-91.90

Price-Earnings ratio-91.90

Dividend yield

3.28%

Dividend yield3.28%

Average volume

6.39M

Average volume6.39M

High today

$24.75

High today$24.75

Low today

$24.13

Low today$24.13

Open price

$24.29

Open price$24.29

Volume

4.04M

Volume4.04M

52 Week high

$40.49

52 Week high$40.49

52 Week low

$21.33

52 Week low$21.33

BAX News

Simply Wall St 4d

Baxter International: Assessing Valuation After Hemopatch Launch Sparks Investor Interest

Baxter International (BAX) just introduced its new Hemopatch sealing hemostat, a product built with direct input from surgeons to better meet real-world needs i...

Simply Wall St 6d

What Baxter International's Surgeon-Inspired Hemopatch Launch Reveals About Its Innovation Trajectory

Earlier this week, Baxter International unveiled its new Hemopatch sealing hemostat, a room-temperature collagen pad developed over ten years with direct input...

Analyst ratings

63%

of 19 ratings

Buy

26.3%

Hold

63.2%

Sell

10.5%

People also own

Based on the portfolios of people who own BAX. This list is generated using Robinhood data, and it’s not a recommendation.